Baird raised the firm’s price target on Nurix Therapeutics to $25 from $24 and keeps an Outperform rating on the shares. The firm continues to like the shares because they believe the data is strengthening that BTK degraders can provide benefits that BTK inhibitors do not, and they believe the clinical data for BTK degrader NX-5948 is likely to be stronger at the next update in mid-2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics, Inc. Reported Earnings. Did it Beat Estimates?
- Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
- Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
- Nurix eligible for $2.5B in research collaboration with Sanofi for ‘STAT6’
- Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
